GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
DCLK1 | 2700 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0159 | 28244691
|
NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 27996162
|
NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 28244691
|
NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 28244691
|
NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 31508487
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 27996162
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 28244691
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 28244691
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5695 | 31508487
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 30486896
|
BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | Western Blotting followed by SFA | NA | 0.28 | 0.1135 | 30486896
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | Western Blotting followed by SFA | NA | 0.28 | 0.456 | 30486896
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.28 | 0.456 | 31508487
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.28 | 0.456 | 27996162
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.28 | 0.456 | 28244691
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.28 | 0.456 | 28244691
|
ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0604 | 31508487
|
ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.1739 | 31508487
|
ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.684 | 31508487
|
CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0498 | 31508487
|
EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.211 | 31508487
|
KLF4 | 6348 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0891 | 31508487
|
POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.6448 | 31508487
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | NA | FACs | NA | 0.12 | 0.7582 | 31558702
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.12 | 0.7582 | 27996162
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.12 | 0.7582 | 28244691
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Patu8988 | Gemcitabine | FACs followed by SFA | NA | 0.12 | 0.7582 | 28244691
|